{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-058729","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2025-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.606124+00:00","generated_at":"2026-05-16T12:15:08.865556+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Skye Bioscience licenses Halozyme's ENHANZE technology for subcutaneous nimacimab","bullets":["Non-exclusive license to Halozyme's ENHANZE drug delivery tech for subcutaneous nimacimab formulation.","Halozyme to be exclusive supplier of clinical and commercial rHuPH20 API for the product.","Milestone payments tied to development, commercialization, and net sales levels; mid-single digit royalties on worldwide net sales.","Agreement includes customary termination rights, reps, warranties, and indemnification."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-058729","json":"https://secwatch.observer/filing/0001628280-25-058729.json","markdown":"https://secwatch.observer/filing/0001628280-25-058729.md","text":"https://secwatch.observer/filing/0001628280-25-058729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000162828025058729/0001628280-25-058729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000162828025058729/skye-20251218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:15:08.865556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}